# NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Source: https://onco.cc/trials/nct06405490/  
OnCo record `nct06405490` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cAPOX (capecitabine, oxaliplatin), capecitabine and cadonilimab in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.

## Summary

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC is a phase 2, interventional study registered as NCT06405490 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 30 participants, started 2024-04-17 and due to reach its primary completion in 2026-08-30. Interventions recorded: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab. Conditions listed: Nanoliposomal Irinotecan; Cadonilimab; Oxaliplatin; Capecitabine; First-Line; Advanced Cancer; Pancreatic Adenocarcinoma; Drug Use. Primary outcome: Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06405490
- Phase: 2
- Setting: Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II Study
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06405490: https://clinicaltrials.gov/study/NCT06405490

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06405490.json